type B3 thymoma and thymic carcinoma research hub

EORTC-1525-LCG: Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym)

This study, named Nivothym, is looking at new treatments for a rare type of cancer called thymoma or thymic carcinoma. It's testing two medicines, ipilimumab and nivolumab, to see if they can help patients whose cancer has come back after chemotherapy. The main goal is to see if the cancer stays stable for at least six months.